ARVN
Arvinas, Inc.
NASDAQ · USHealthcareBiotechnology
$8.02+0.12%
Price as of Jul 20, 2026
ARVN growth
Arvinas, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -79.1%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- -1.6%
- Operating cash flow
- -1.4%
Forward estimates
- Revenue
- +7.2%
- EBITDA
- +62.7%
- EPS
- -13.3%
Three-year CAGR
- Revenue
- +26.0%
- EBITDA
- +60.7%
- EBIT
- +54.1%
- Net income
- +59.4%
- EPS
- +53.8%
- Free cash flow
- -5.6%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.